文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌诊断是否带来更高的戒烟率?来自Medicare健康结局调查的发现

Does the Diagnosis of Bladder Cancer Lead to Higher Rates of Smoking Cessation? Findings from the Medicare Health Outcomes Survey.
PubMed 文献 · J Urol · 2019-07-08

该研究利用1998至2013年SEER-MHOS数据,将394例新诊断膀胱癌患者与倾向匹配的1970例非癌对照及169例肾细胞癌患者比较。膀胱癌患者戒烟率为27%,非癌对照为21%,肾细胞癌为26%,组间无显著差异。作者认为戒烟比例总体偏低,需加强利用这一可教育时机。

要点

  • 膀胱癌患者戒烟率27%,与倾向匹配非癌对照21%无显著差异。
  • 膀胱癌与肾细胞癌患者戒烟率26%相比无显著差异。
  • 年龄、非裔美国人种族和大学教育是膀胱癌患者戒烟的独立预测因素。

核心结论

  • 与倾向匹配的非癌对照相比,膀胱癌诊断后戒烟率无显著差异。
  • 戒烟者比例总体偏低,作者认为需要改进努力以利用膀胱癌患者的这一可教育时机。

研究设计与样本

  • 基于1998至2013年SEER-MHOS数据,纳入诊断前后均有调查数据的所有新发膀胱癌患者。
  • 将394例新诊断膀胱癌患者与倾向匹配的1970例非癌对照比较,并与169例新发肾细胞癌患者比较。
  • 采用多变量逻辑回归评估戒烟的可能性。

主要发现

  • 膀胱癌患者基线吸烟率为16%,肾细胞癌患者为11%,差异无统计学意义。
  • 膀胱癌患者戒烟率为27%,非癌对照为21%,肾细胞癌患者为26%(p值分别为0.30和0.90)。
  • 膀胱癌患者与非癌对照相比调整后戒烟OR为1.3(95%CI 0.7-2.5),肾细胞癌患者与非癌对照相比调整后戒烟OR为1.2(95%CI 0.4-3.6),差异无统计学意义。
  • 膀胱癌患者戒烟的独立预测因素包括年龄(p=0.03)、非裔美国人种族(p=0.03)和大学教育(p=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Smoking is the most common risk factor for bladder cancer and it is associated with adverse clinical outcomes. The bladder cancer diagnosis represents a teachable moment for smoking cessation. We investigated the likelihood of smoking cessation after bladder cancer diagnosis in a population database. MATERIALS AND METHODS: We evaluated the 1998 to 2013 SEER (Surveillance, Epidemiology and End Results)-MHOS (Medicare Health Outcomes Survey) data on all patients diagnosed with incident bladder cancer on whom survey data were available before and after diagnosis. We compared these patients to propensity matched noncancer controls and to a cohort of patients with incident renal cell carcinoma. Differences in smoking cessation were compared between the groups and multivariate logistic regression was performed to assess the likelihood of smoking cessation. RESULTS: We propensity matched 394 patients with newly diagnosed bladder cancer to 1,970 noncancer controls and compared them with 169 patients with incident renal cell carcinoma. Baseline smoking prevalence was more common in patients diagnosed with bladder cancer compared to renal cell carcinoma (16% vs 11%) but the difference was not significant. The smoking cessation rate in patients with bladder cancer was 27% compared with 21% in noncancer controls and 26% in patients with renal cell carcinoma (p = 0.30 and 0.90, respectively). There was no significant difference in the adjusted OR of quitting smoking in patients with bladder cancer vs those with renal cell carcinoma compared to noncancer controls (OR 1.3, 95% CI 0.7-2.5 vs OR 1.2, 95% CI 0.4-3.6). Independent predictors of smoking cessation in patients with bladder cancer included age (p = 0.03), African American race (p = 0.03) and college education (p = 0.01). CONCLUSIONS: Compared to propensity matched noncancer controls smoking cessation did not significantly differ after a diagnosis of bladder cancer. The proportion of individuals who quit was low overall, suggesting that improved efforts are needed to use this teachable moment in patients with bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Winters BR, Wen L, Holt SK, et al. Does the Diagnosis of Bladder Cancer Lead to Higher Rates of Smoking Cessation? Findings from the Medicare Health Outcomes Survey. J Urol. 2019. PMID: 30835630. doi:10.1097/JU.0000000000000206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。